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Abstract: Although attention has been given to thromboprophylaxis for atrial fibrillation (AF) 
in present treatment guidelines, practical, clinical antithrombotic therapy is poorly developed 
for very elderly patients. We reviewed the records of 105 consecutive patients with AF of 
mean age 85 years, to determine how the greatest benefits from antithrombotic therapy could 
be obtained in this group. The mean CHADS2 score in these patients was 3.1 ± 1.5. Before 
antithrombotic therapy, 21.0% of the patients had diseases with a risk of hemorrhage, 26.7% 
had diseases with a risk of thrombosis, and 8.6% had diseases with a risk of both hemorrhage 
and thrombosis. Moreover, 89 patients (84.8%) were receiving a single antiplatelet drug, 
10 (9.5%) used aspirin plus clopidogrel, and six (5.7%) were taking an oral anticoagulant (OAC). 
Additionally, dual antiplatelet therapy was more commonly given to patients with permanent 
AF (paroxysmal and persistent versus permanent, 6.3% and 12.5% versus 30%, respectively, 
Chi-square = 8.4, P = 0.010). The incidence of adverse events was 25.7%, with thromboembolic 
events in 20.0% and hemorrhage in 5.7% of patients. There were no thromboembolic events in 
those patients taking OACs, but 33% of patients who took OACs had bleeding complications. 
It is difficult to choose appropriate antithrombotic strategies in very elderly patients. Both the 
  thrombotic risk and the bleeding risk should be considered for helping such patients derive 
optimal benefit from thromboprophylaxis for AF.
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and it increases in 
prevalence with age, ranging from 0.5% in people aged 50–59 years to almost 9% 
in people aged 80 years. Heart failure, stroke, and thromboembolic events are its 
severe complications.1–3 When strokes occur in association with AF, patients have 
substantial mortality, morbidity, disability rates, and longer hospital stays.4 Given 
the increasing prevalence of AF and its associated thromboembolic complications, 
the present treatment guidelines (such as the Guideline for Prevention of Stroke in 
Patients with Ischemic Stroke or Transient Ischemic Attack, American College of 
  Cardiology [ACC], American Heart Association [AHA], 2006; Antithrombotic Therapy 
in Atrial Fibrillation, ACCP8th, 2008) have focused on the use of thromboprophylaxis 
for AF.5,6 Antithrombotic medicines include anticoagulant and antiplatelet drugs. 
The overwhelming consensus of the research has proven that the oral anticoagulant 
(OAC) warfarin is more effective than aspirin in preventing strokes for patients 
with AF. The management of antithrombotic treatment in the very elderly with 
an indication for warfarin is challenging, due to the need to balance carefully the Clinical Interventions in Aging 2010:5 158
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risk of thromboembolism with that of hemorrhage. Thus, 
what is the situation in the real world for practical, clinical 
  antithrombotic therapy according to the guidelines for AF in 
elderly patients? How can adequate and safe anticoagulation 
be achieved in an elderly population?
Scant data are available on the safety and efficacy of 
antithrombotic strategies that are adopted in elderly patients 
according to the guidelines. The present study aimed to 
determine the possible factors influencing the success of 
antithrombotic therapy in very elderly patients with AF, 
and to explore how the greatest benefits from antithrombotic 
therapy could be obtained in such a population group.
Methods
Study population
The study population was retrospectively identified using 
an electronic clinical information systems database. All 
  demographic and laboratory data were obtained from medical 
records. Eligible patients were aged 70 years. The patients 
were divided into three groups, ie, a group aged 70–79, 
a group aged 80–89, and a group aged over 90 years. Patients 
who had a pre-existing diagnosis of permanent, persistent, or 
paroxysmal AF and patients who developed new onset of AF 
during their current admission were included in this analysis. 
AF was diagnosed and classified according to the guidelines 
of ACC, AHA, and European Society of Cardiology (ESC).7 
Exclusion criteria included rheumatic valvular heart disease 
and prosthetic heart valves. A follow-up was performed to 
ascertain outcomes, ie, episodes of hemorrhage, thrombotic 
events, and mortality. Hemorrhage included major and minor 
bleeding. Major bleeding was defined as an intracranial 
  hemorrhage, a decrease in blood hemoglobin level of more 
than 5.0 g/dL, the need for a transfusion of two or more units 
of blood, the need for corrective surgery, or any combination 
of these events. Minor bleeding was defined as a subcutaneous 
ecchymosis or hematoma, gastrointestinal bleeding, or bloody 
sputum. Thrombotic events included stroke, transient ischemic 
attack, atrial thrombosis, pulmonary thromboembolism 
(PT), deep vein thrombosis (DVT), and peripheral vascular 
  thrombosis. The stroke risk of our patients was assessed by the 
CHADS2 score (assigning one point each for the presence of 
congestive heart failure, hypertension, age 75 years or older, 
and diabetes mellitus, and assigning two points for a history 
of stroke or transient ischemic attack).8
Statistical analysis
Continuous variables were evaluated for normal distribution 
by the Kolmogorov–Smirnov test. The normally distributed 
continuous variables are shown as means ± standard 
  deviations (SDs), and nonparametrically distributed variables 
are shown as medians (interquartile ranges). Discrete vari-
ables are presented as frequencies (percentages). Discrete 
variables were compared via the Chi-square test or (when the 
2 × 2 table had five patients) the Fisher test. Comparisons 
of the groups for continuous variables were performed with 
ANOVA for independent samples that were parametrically 
distributed. All P values were two-sided, and a P value of 
0.05 was considered to be statistically significant. Analyses 
were performed with SPSS 13.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
Between 2001 and 2008, we reviewed 105 patients (92.4% 
men, mean age of 84.9 ± 6.1 years) with AF, of whom 79 
(75.2%) had paroxysmal AF, 16 (15.2%) had persistent AF, 
and 10 (9.5%) had permanent AF. The population was older, 
with diabetes mellitus in 43.8%, hypertension in 65.7%, heart 
failure or impaired cardiac function in 51.4%, and previous 
coronary events in 86.7%. The mean CHADS2 score was 
3.1 ± 1.5. Demographic characteristics and risk factors for 
stroke are presented in Table 1.
Comorbid diseases in elderly  
patients with AF
A total of 22.9% of the elderly patients suffered from cancer. 
Twenty-two patients (21.0%) had diseases with a risk of 
  hemorrhage, while 28 (26.7%) had diseases with a risk of 
thrombosis. Additionally, nine patients (8.6%) had diseases 
with a risk of both hemorrhage and thrombosis. Compared with 
the young elderly patients, the very elderly patients (aged over 
90 years) had a significantly increased prevalence of diseases 
with risks of both hemorrhage and thromboses (Table 2).
Antithrombotic drug regimen
The  mean  antithrombotic  therapy  duration  was 
15.2  ±  6 years (range 0.7–32 years). Although the tar-
get INR (international normalized ratio) was 2.0 (range 
1.6–2.5; AHA/ASA, 2006), INR values between 1.5 and 
1.8 were considered adequate for very elderly patients aged 
over 80 years who were taking OACs. For patients who 
developed intracerebral hemorrhage after ischemic stroke, 
all anticoagulants and antiplatelet drugs were discontinued 
during the acute period for two weeks after the hemorrhage, 
and OAC usage was resumed after three months. Further-
more, for patients with recurrent thromboembolic events Clinical Interventions in Aging 2010:5 159
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(such as DVT, PE, and venous thrombosis associated with 
the placement of a central venous catheter) who required 
anticoagulation soon after a cerebral hemorrhage, intrave-
nous heparin treatment was given for two weeks, and OAC 
with a dosage of 1.5 mg/day was continued, with rigorous 
monitoring and maintenance of INR in the lower end of 
the therapeutic range.
Of the 105 patients, 99 patients (94.3%) were receiving 
antiplatelet drugs, whereas six patients (5.7%) were taking 
OAC warfarin (Table 3). Dual antiplatelet therapy (aspirin 
plus clopidogrel) was more commonly given to patients 
  suffering with permanent AF (Table 4).
Adverse events with antithrombotic 
therapy in elderly patients
The incidence of adverse events in elderly patients with AF was 
high (25.7%), with hemorrhage in 5.7% and thromboembolic 
events in 20.0% (Table 5). Among the hemorrhage cases, one 
case was major bleeding (in patients taking OAC), and five 
cases were minor bleeding events (Table 6).
Table 1 Baseline characteristics of the study population
Characteristic Total sample (n = 105) 70–79 years (n = 22) 80–89 years (n = 64) 90 years (n = 19)
Mean age, years (SD) 84.9 (6.1) 76.2 (2.9) 85.2 (2.7) 93.5 (2.7)
Sex
Male, n (%) 97 (92.4) 21 (95.5) 58 (90.6) 18 (94.7)
Female, n (%) 8 (7.6) 1 (4.6) 6 (9.4) 1 (5.3)
AF type
Paroxysmal AF, n (%) 79 (75.2) 19 (86.3) 44 (68.8) 16 (84.2)
Persistent AF, n (%) 16 (15.2) 2 (9.1) 12 (18.8) 2 (10.5)
Permanent AF, n (%) 10 (9.5) 1 (4.6) 8 (12.5) 1 (5.3)
Past medical history
Hypertension, n (%) 69 (65.7) 14 (63.6) 42 (65.6) 14 (21.1)
Diabetes, n (%) 46 (43.8) 8 (36.4) 30 (46.9) 9 (47.4)
CHF, n (%) 54 (51.4) 7 (31.8) 34 (53.1) 13 (68.4)
CAD, n (%) 91 (86.7) 16 (72.7) 60 (93.8) 15 (79.0)
Stroke/TIA, n (%) 24 (22.9) 3 (13.6) 10 (15.6) 11 (57.9)
CHADS2 risk scores
Mean CHADS2 scores (SD)* 3.1 (1.5) 2.4 (1.3) 3.0 (1.4) 4.1(1.4)
  Low (score 0), n (%) 2 (0.02) 2 (0.09) 0 (0) 0 (0)
  Intermediate (score 1–2) n (%) 41 (39.1) 9 (40.9) 29 (45.3%) 3 (27.3%)
  High risk (score 3–6) n (%) 54 (51.4) 11 (50.0) 35 (54.7%) 8 (72.7%)
Notes: CHADS2 score = one point each for the presence of congestive heart failure, hypertension, age 75 years or older, and diabetes mellitus, two points for a history of 
stroke or transient ischemic attack. *ANOvA, F = 8.2, P  0.05. The P value represents the comparison of the group aged 70–79 years, the group aged 80–89 years, and the 
group aged over 90 years.
Abbreviations: AF, atrial fibrillation; CHF, chronic heart failure; CAD, coronary heart disease; SD, standard deviation.
Table 2 Comorbid diseases in elderly patients with atrial fibrillation before antithrombotic therapy
Total sample (n = 83) 70–79 years (n = 22 ) 80–89 years (n = 64) 90 years (n = 19) χ2 P
Cancer* n (%) 24 (22.9) 3 (13.6) 16 (25.0) 5 (26.3) 75.1 0.000
Diseases with risk of 
  hemorrhage* n (%)
22 (21.0) 3 (13.6) 12 (18.8) 7 (36.8) 71.1 0.000
Diseases with risk of 
  thromboembolism* n (%)
28 (26.7) 4 (18.2) 11 (17.2) 13 (68.4) 93.6 0.000
Diseases with risk 
of hemorrhage and 
  thromboembolism* n (%)
9 (8.6) 2 (9.1) 3 (4.7) 4 (21.1) 145 0.000
Notes: Cancers included meningioma, pharynx nasalis squamous carcinoma, suprahyoid gland adenoma, pulmonary cancer, gastric interstitialoma, gastric carcinoma, carcinoma 
of gastric cardia, liver cancer, sigmoid colon cancer, suprarenal epithelioma, kidney papillocarcinoma, carcinoma of the bladder, prostatic carcinoma and chronic lymphocytic leu-
kemia. Diseases with a risk of hemorrhage were brain hemorrhage, hemorrhagic gastritis, duodenal ulcer, renal anemia and thrombocytopenia; in contrast, diseases with a risk of 
thromboembolism included lacunar cerebral infarction, vertebrobasilar artery insufficiency, atrial thrombosis, deep venous thrombosis, and peripheral vascular thrombosis.
*Chi-square test, P  0.05. The P value represents the comparison of the group aged 70–79 years, the group aged 80–89 years, and the group aged over 90 years.Clinical Interventions in Aging 2010:5 160
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Discussion
A population-based study in China revealed that 0.8% of 
  Chinese are currently afflicted by AF, with an absolute 
  number of over 10 million, and the prevalence of this 
  disease will increase with the expansion of the elderly in this 
  population.9,10 Based on the Chinese population census, the 
elderly (60 years) currently account for 11% of the general 
  population, and the estimated number of AF patients in China 
is set to surpass 25 million. The present study illustrates 
that various antithrombotic drugs were used in very elderly 
  Chinese patients with AF who had a mean age of 85 years. 
We showed that anticoagulants should have been used to 
prevent thromboembolic events in these elderly patients with 
AF, as most of them were at high risk for stroke according 
to their CHADS2 scores (mean CHADS2 score of 3.1).11 
In fact, most of the elderly patients in this study used aspirin 
or clopidogrel, while only 6% of patients used warfarin. 
This is in agreement with data from another retrospective 
study by Qi et al, involving 41 major hospitals and 9,297 AF 
patients in China, which showed that long-term treatment 
with anticoagulants was used in only 6.6% of patients.10 
So a wide gap exists between the antithrombotic therapy 
  guidelines for AF and actual clinical practice in the very 
elderly with AF in China.
Why is it difficult to choose the appropriate antithrombotic 
therapy regimen in very elderly patients? The main reason that 
antithrombotic therapy is difficult in elderly patients is that 
they tend to have more comorbidities. Before antithrombotic 
therapy began in this study, 21.0% of the patients had diseases 
with a risk of hemorrhage, 26.7% of the patients had diseases 
with a risk of thrombosis, and 8.6% patients had diseases with 
a risk of both hemorrhage and thrombosis. In addition, the 
risks of hemorrhage and thromboembolism are significantly 
increased in very elderly patients compared with young 
elderly patients. Those patients aged 90 years or more were 
five times more likely to develop diseases with risks of both 
hemorrhage and thromboembolism compared with those 
aged 80 years. For elderly patients who have hemorrhagic 
gastritis, duodenal ulcers, renal anemia, thrombocytopenia, or 
a past medical history of brain hemorrhage, it is quite difficult 
to choose appropriate antithrombotic therapy. Another 
  reason for difficulty using antithrombotic therapy is that the 
  incidence of cancer is high in very elderly patients (22.9% 
in patients in this study). All of the above-mentioned factors, 
including the greater number of comorbidities, the higher 
risks of hemorrhage and thromboembolism, and shorter life 
expectancy, can influence decision-making regarding an 
antithrombotic strategy in very old patients.
In addition, our study illustrated that the incidence of 
adverse events after antithrombotic therapy in elderly patients 
with AF was high, with thromboembolic events in 21% and 
hemorrhage in 6%. These results suggested that antiplatelet 
drugs for the very elderly with AF did not efficiently prevent 
thromboembolic events, and dual antiplatelet therapy also did 
not show any better thromboprophylactic effects compared 
with OAC. Our results are consistent with those of the 
ACTIVE-W trial.12 The survey revealed that the stroke rates 
for those patients even with a CHADS2 score = 1 were 1.25% 
per year on aspirin and clopidogrel, and 0.43% per year on an 
anticoagulant, which represents nearly a three-fold difference. 
In a similar series of patients in the Birmingham Atrial 
Fibrillation Treatment of the Aged study, a substantial benefit of 
Table 3 Antithrombotic regimen adopted in elderly patients with atrial fibrillation
Total sample (n = 105) 70–79 years (n = 22) 80–89 years (n = 64) 90 years (n = 19) χ2 P
Aspirin* n (%) 42 (40.0%) 14 (63.6%) 20 (31.3%) 8 (42.1%) 33.5 0.000
Clopidogrel n (%) 47 (44.8%) 9 (40.9%) 33 (51.6%) 5 (26.3%) 10.2 0.003
Aspirin plus clopidogrel† n (%) 10 (9.5%) 1 (4.6%) 9 (14.1%) 0 3.3 0.228
warfarin† n (%) 6 (5.7%) 1 (4.6%) 4 (6.3%) 1 (5.3%) 4.8 0.105
Notes: *Chi-square test, P  0.001. The P value represents the comparison of the group aged 70–79 years, the group aged 80–89 years, and the group aged 90 years. 
†Fisher’s exact test.
Table 4 AF type and outcomes of antithrombotic therapy
Paroxysmal AF (n = 79) Persistent AF (n = 16) Permanent AF (n = 10) χ2 P
Aspirin† n (%) 35 (44.3) 6 (37.5) 1 (10.0) 6.4 0.041
Clopidogrel* n (%) 36 (45.6) 6 (37.5) 5 (50.0) 10.2 0.006
Aspirin plus clopidogrel† n (%) 5 (6.3) 2 (12.5) 3 (30.0) 8.4 0.010
warfarin† n (%) 3 (3.8) 2 (12.5) 1 (10.0) 5.7 0.064
Notes: *Chi-square test. †Fisher’s exact test. The P value represents the comparison of paroxysmal AF, persistent AF and permanent AF.
Abbreviation: AF, atrial fibrillation.Clinical Interventions in Aging 2010:5 161
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an anticoagulant over aspirin was seen among elderly subjects, 
including those patients with CHADS2 scores of 1–2 or 2.13 
It is well known that thrombogenesis in AF is mainly coagula-
tion factor-related, with red (fibrin-rich) clots predominating 
in AF, as illustrated in some studies in which anticoagulants 
significantly reduced thrombogenesis, whereas aspirin and 
clopidogrel did not.14,15 However, our study showed that 33% 
of patients taking OAC had bleeding complications, and falls 
and dementia were the common factors leading to intracranial 
hemorrhage in the elderly patients taking OAC.16,17
In clinical practice, there is still an indication for long-term 
OAC use for patients who have major bleeding events after 
antithrombotic therapy, but the “when” and “how” of resuming 
antithrombotic treatment are the challenging problems. 
Unfortunately, the optimal antithrombotic treatment for this 
population is currently unknown. There are no randomized 
studies assessing the best regimen in this setting. Generally 
speaking, for patients who develop intracerebral hemorrhage 
after ischemic stroke, OAC should be resumed after three to 
six months. For patients with recurrent thromboembolic events 
(such as DVT, PE, and venous thrombosis associated with the 
placement of a central venous catheter) who required anticoag-
ulation soon after a cerebral hemorrhage, intravenous heparin 
treatment should be given for two weeks, followed by continued 
OAC with rigorous monitoring and maintenance of the INR 
in the lower end of the therapeutic range (AHA/ASA, 2006). 
However, for the patient in this study who had a new onset of 
peripheral vascular thrombosis at 40 days after intracerebral 
hemorrhage secondary to ischemic stroke, OAC treatment with 
a daily dosage of 1.5 mg proved to be effective for prevention 
of thromboembolism, with rigorous maintenance of INR at 
no more than 1.8.
Our results suggest the optimal antithrombotic therapy 
  selection for this population must be mainly accomplished 
based on individual and accurate risk stratification for both 
  thromboembolism and hemorrhage during therapy, not 
based only on the risks before treatment. Age over 75 years, 
  hemorrhoids, rhinorrhagia, hemorrhagic gastritis, duodenal 
ulcers, renal anemia, thrombocytopenia, a hemorrhagic 
  history, and INR intensity should be considered when 
  assessing the patient’s bleeding risk.
Additionally, the anticoagulation therapy must be 
very closely controlled in all patients who receive OAC, 
  especially if a high bleeding risk is present. In our experience, 
  maintaining the INR value within the range of 1.5–1.8 by 
frequent monitoring of OAC therapy patients was safe and 
effective in the very elderly. According to clinical practical 
guidelines for AF based on the consensus opinion of Chinese 
experts, the target INR should be sustained at 1.8 (range 
1.5–2.0) in patients aged over 75 years who are at high risk of 
bleeding. However, in this study, maintaining INR between 
1.6 and 1.8 was sufficient for preventing hemorrhage and 
thromboembolism in elderly patients who required long-term 
anticoagulation soon after bleeding events. The maximal 
tolerated dosage of OAC is likely to be lower for Chinese 
patients compared with Caucasian patients. A recent study 
by Shen et al showed that Asians with AF were at greater 
risk for warfarin-related intracranial hemorrhage.18
Moreover, for AF patients at high risk of arterial and 
venous thrombosis or multiple episodes of thrombosis (for 
Table 5 Adverse events after thromboembolic therapy in elderly patients with atrial fibrillation
Total sample (n = 29) 70–79 years (n = 22 ) 80–89 years (n = 64) 90 years (n = 19)
Hemorrhage, n (%) 6 (5.7) 3 (13.6) 3 (4.7) 0 (0)
embolism, n (%) 21 (20.0) 4 (18.2) 15 (23.4) 2 (10.5)
Table 6 Clinical outcomes in geriatric patients with atrial fibrillation receiving different antithrombotic therapy regimens
Outcome Aspirin (n = 43) Clopidogrel (n = 47) Aspirin + Clopidogrel (n = 10) Warfarin (n = 6)
Hemorrhage (%)
Major bleeding, n (%) 0 (0) 0 (0) 0 (0) 1 (16.7)
Minor bleeding, n (%) 2 (4.7) 1 (2.1) 1 (10.0) 1 (16.7)
Thromboembolic events (%)
Stroke/TIA, n (%) 5 (11.6) 6 (12.8) 2 (20.0) 0 (0)
Systemic embolus n (%) 3 (7.0) 4 (8.5) 1 (10.0) 0 (0)
Notes: Major bleeding was defined as an intracranial hemorrhage, a decrease in blood hemoglobin level of more than 5.0 g/dL, need for a transfusion of two or more units of 
blood, need for corrective surgery or any combination of these events. Minor bleeding was defined as a subcutaneous ecchymosis or hematoma, gastrointestinal bleeding or 
bloody sputum. Systemic emboli included atrial thrombosis, pulmonary thromboembolism, deep vein thrombosis, and peripheral vascular disease.
Abbreviation: TIA, transient ischemic attack.Clinical Interventions in Aging 2010:5
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example, patients with a history of chronic obstructive 
pulmonary disease, mechanical ventilation, varicosity, 
dehydration, aggravated heart failure, concurrence of DVT, 
or ischemic stroke), heparin treatment could be initiated for 
two weeks and followed with OAC.
Finally, further studies are required to find a more powerful 
tool for predicting the bleeding risk in everyday practice 
in this setting in order to achieve optimal antithrombotic 
therapy. Large, randomized studies are needed to explore 
the best therapeutic strategies in patients who have major 
bleeding events after antithrombotic therapy and who require 
antithrombotic treatment soon thereafter.
The limitations of this study were the small sample size 
and the possibility that the rates of events may have been 
underreported. Therefore, further large-sample studies are 
required to verify the recommendations made in terms of 
individualization of antithrombotic therapy for patients with 
a high risk of hemorrhage and thromboembolism.
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